GlycoMimetics Inc. [NASDAQ: GLYC] stock went on a downward path that fall over -4.37% on Friday, amounting to a one-week price increase of more than 5.70%. The company report on May 3, 2021 that GlycoMimetics Reports Highlights and Financial Results for First Quarter 2021.
GlycoMimetics continues to target year-end 2021 for completing enrollment of the Company-sponsored pivotal trial evaluating uproleselan in patients with relapsed/refractory acute myeloid leukemia (AML).
Enrollment in the Phase 2 portion of the NCI-sponsored Phase 2/3 registration trial evaluating uproleselan in newly diagnosed AML patients fit for chemotherapy is expected to complete by year-end 2021 and to support a subsequent interim analysis based on event-free survival.
Over the last 12 months, GLYC stock dropped by -16.61%. The average equity rating for GLYC stock is currently 2.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $129.90 million, with 50.70 million shares outstanding and 46.60 million shares in the current float. Compared to the average trading volume of 895.46K shares, GLYC stock reached a trading volume of 1762418 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on GlycoMimetics Inc. [GLYC]:
ROTH Capital have made an estimate for GlycoMimetics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 14, 2019. While these analysts kept the previous recommendation, SunTrust raised their target price from $23 to $5. The new note on the price target was released on August 05, 2019, representing the official price target for GlycoMimetics Inc. stock. Previously, the target price had yet another drop from $20 to $6, while Piper Jaffray kept a Neutral rating on GLYC stock.
The Average True Range (ATR) for GlycoMimetics Inc. is set at 0.20, with the Price to Sales ratio for GLYC stock in the period of the last 12 months amounting to 59.05. The Price to Book ratio for the last quarter was 0.98, with the Price to Cash per share for the same quarter was set at 2.46.
GLYC Stock Performance Analysis:
GlycoMimetics Inc. [GLYC] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.70. With this latest performance, GLYC shares dropped by -5.49% in over the last four-week period, additionally sinking by -33.97% over the last 6 months – not to mention a drop of -16.61% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GLYC stock in for the last two-week period is set at 44.71, with the RSI for the last a single of trading hit 48.96, and the three-weeks RSI is set at 42.76 for GlycoMimetics Inc. [GLYC]. The present Moving Average for the last 50 days of trading for this stock 2.81, while it was recorded at 2.31 for the last single week of trading, and 3.41 for the last 200 days.
Insight into GlycoMimetics Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and GlycoMimetics Inc. [GLYC] shares currently have an operating margin of -506.84. GlycoMimetics Inc.’s Net Margin is presently recorded at -502.09.
Return on Total Capital for GLYC is now -35.66, given the latest momentum, and Return on Invested Capital for the company is -35.54. Return on Equity for this stock declined to -36.14, with Return on Assets sitting at -32.84. When it comes to the capital structure of this company, GlycoMimetics Inc. [GLYC] has a Total Debt to Total Equity ratio set at 2.20. Additionally, GLYC Total Debt to Total Capital is recorded at 2.15, with Total Debt to Total Assets ending up at 1.97. Long-Term Debt to Equity for the company is recorded at 1.50, with the Long-Term Debt to Total Capital now at 1.47.
Reflecting on the efficiency of the workforce at the company, GlycoMimetics Inc. [GLYC] managed to generate an average of -$944,943 per employee. Receivables Turnover for the company is 108.06 with a Total Asset Turnover recorded at a value of 0.07.GlycoMimetics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 12.30 and a Current Ratio set at 12.30.
GLYC Stock EPS
With the latest financial reports released by the company, GlycoMimetics Inc. posted -0.32/share EPS, while the average EPS was predicted by analysts to be reported at -0.38/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 15.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GLYC.
GlycoMimetics Inc. [GLYC] Insider Position Details
There are presently around $95 million, or 79.70% of GLYC stock, in the hands of institutional investors. The top three institutional holders of GLYC stocks are: BVF INC/IL with ownership of 9,544,262, which is approximately 31.749% of the company’s market cap and around 2.10% of the total institutional ownership; NEA MANAGEMENT COMPANY, LLC, holding 9,089,041 shares of the stock with an approximate value of $21.91 million in GLYC stocks shares; and BLACKROCK INC., currently with $6.8 million in GLYC stock with ownership of nearly 7.916% of the company’s market capitalization.
Positions in GlycoMimetics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 50 institutional holders increased their position in GlycoMimetics Inc. [NASDAQ:GLYC] by around 6,810,355 shares. Additionally, 33 investors decreased positions by around 9,412,786 shares, while 17 investors held positions by with 23,010,859 shares. The mentioned changes placed institutional holdings at 39,234,000 shares, according to the latest SEC report filing. GLYC stock had 20 new institutional investments in for a total of 1,600,804 shares, while 11 institutional investors sold positions of 8,546,839 shares during the same period.